```html

Xanthomas Tuberosum (Tuberous Xanthoma)

Overview

Xanthomas tuberosum, also called tuberous xanthoma, is a type of cutaneous xanthoma characterized by firm, yellow‑orange nodules that develop over pressure‑bearing areas such as the elbows, knees, buttocks, and heels. These lesions are composed of lipid‑laden macrophages (foam cells) that accumulate in the dermis and subcutaneous tissue.

The condition most often reflects an underlying disorder of lipid metabolism, especially severe elevations of low‑density lipoprotein cholesterol (LDL‑C) caused by familial hypercholesterolemia (FH) or other primary hyperlipidemias. While the skin findings themselves are benign, they serve as a visible warning sign for systemic atherosclerotic disease.

• Typical age of onset: Late childhood to early adulthood (10‑30 years) when FH is present; can appear later in secondary hyperlipidemia.
• Gender: No strong sex predilection, though severe FH is slightly more common in males.
• Prevalence: Tuberous xanthomas are rare in the general population but occur in up to 10‑15 % of patients with homozygous FH and 1‑2 % of those with heterozygous FH.<sup>[1]</sup>

Symptoms

The hallmark of tuberous xanthoma is the presence of palpable nodules. The full symptom spectrum includes:

Cutaneous lesions

• Appearance: Yellow‑orange, firm, often slightly raised plaques or nodules.
• Location: Extensor surfaces—elbows, knees, buttocks, knuckles, Achilles tendon, and occasionally the palms or soles.
• Size: Ranges from a few millimeters to >2 cm in diameter.
• Texture: Hard, non‑compressible; may feel like a small lump under the skin.

Associated systemic symptoms (reflecting underlying lipid disorder)

• Fatigue or reduced exercise tolerance (due to early atherosclerosis).
• Chest pain or angina in older patients with untreated hypercholesterolemia.
• History of premature cardiovascular events (myocardial infarction, stroke) in the family.

Rare presentations

• Ulceration or secondary infection of a large xanthoma.
• Joint pain if xanthomas infiltrate tendons (e.g., tendon xanthomas).

Causes and Risk Factors

Tuberous xanthomas result from the deposition of cholesterol‑rich foam cells in the skin. The primary drivers are disorders that markedly raise plasma LDL‑C or other atherogenic lipids.

Genetic causes

• Familial hypercholesterolemia (FH): Mutations in the LDLR, APOB, or PCSK9 genes cause lifelong elevation of LDL‑C. Homozygous FH (HoFH) leads to LDL‑C > 500 mg/dL and a 20‑30 % prevalence of tuberous xanthomas.<sup>[2]</sup>
• Familial combined hyperlipidemia (FCHL): Overproduction of VLDL leads to high LDL‑C and triglycerides.
• Sitosterolemia: Plant sterol accumulation can also produce xanthomas.

Secondary causes

• Uncontrolled diabetes mellitus (type 2) with dyslipidemia.
• Hypothyroidism (raises LDL‑C).
• Nephrotic syndrome (elevated LDL‑C and triglycerides).
• Medications that raise lipids (e.g., cyclosporine, glucocorticoids, some antiretrovirals).

Risk factors for developing tuberous xanthomas

• LDL‑C > 250 mg/dL sustained for > 2 years.
• Family history of early coronary artery disease (CAD) or xanthomas.
• Male sex (slightly higher risk for severe FH).
• Smoking, obesity, and sedentary lifestyle – these accelerate atherosclerosis and may magnify skin findings.

Diagnosis

Diagnosing tuberous xanthoma involves recognizing the skin lesions and confirming an underlying lipid disorder.

Clinical evaluation

• Detailed skin exam documenting size, number, and distribution of nodules.
• Comprehensive family and personal medical history focusing on hyperlipidemia, cardiovascular events, and endocrine disorders.

Laboratory tests

• Lipid panel: Fasting total cholesterol, LDL‑C, HDL‑C, triglycerides.
• Genetic testing: Targeted sequencing for LDLR, APOB, PCSK9 (especially if FH is suspected).
• Secondary cause work‑up: TSH, fasting glucose/HbA1c, renal function, liver enzymes.

Imaging & procedures

• Dermatologic biopsy: Histology shows foamy macrophages in the dermis; used when diagnosis is uncertain.
• Cardiovascular risk assessment: Carotid ultrasound, coronary calcium scoring, or stress testing if indicated.
• Ultrasound of tendons: Detects concomitant tendon xanthomas (e.g., Achilles).

Diagnostic criteria (adapted from the Dutch Lipid Clinic Network)

A scoring system incorporating family history, clinical signs (including xanthomas), LDL‑C level, and genetic testing helps classify FH as definite, probable, or possible.<sup>[3]</sup>

Treatment Options

Therapy targets two goals: (1) removal or reduction of the cutaneous lesions and (2) aggressive management of the underlying lipid abnormality to prevent cardiovascular disease.

Lipid‑lowering medications

• High‑intensity statins (e.g., rosuvastatin 20‑40 mg, atorvastatin 40‑80 mg): First‑line; can reduce LDL‑C by up to 55 %.<sup>[4]</sup>
• Ezetimibe: Added when statins alone are insufficient; provides an additional 15‑20 % LDL‑C reduction.
• PCSK9 inhibitors (evolocumab, alirocumab): Particularly effective in FH; lower LDL‑C by 60‑70 % and have been shown to regress xanthomas in 30‑50 % of patients after 1–2 years.<sup>[5]</sup>
• Lipid apheresis: Serial plasma filtration used for homozygous FH or refractory cases; removes 60‑70 % of LDL‑C per session.
• Other agents: Bile‑acid sequestrants, fibrates (if triglycerides are also high), and newer agents such as inclisiran (siRNA‑based PCSK9 inhibitor).

Procedural removal of lesions

• Surgical excision: Considered for solitary, large, or cosmetically concerning lesions.
• Laser therapy (CO₂ or Er:YAG): Effective for shallow nodules; minimal scarring.
• Cryotherapy: Less commonly used; risk of ulceration.
• Intralesional steroids: May soften lesions but have limited evidence.

Procedural removal does not address the systemic lipid problem; lesions often recur if hyperlipidemia persists.

Lifestyle modifications

• Diet: Emphasize a heart‑healthy Mediterranean‑style eating pattern—high in fruits, vegetables, whole grains, nuts, olive oil; limited saturated fat, trans fat, and cholesterol.
• Physical activity: ≥150 minutes of moderate‑intensity aerobic exercise per week (or 75 minutes of vigorous activity).
• Weight management: Maintain BMI 18.5‑24.9 kg/m².
• Avoid tobacco and excessive alcohol.

Living with Xanthomas tuberosum (Tuberous Xanthoma)

While the skin lesions are visually noticeable, most patients can lead normal lives with proper medical management.

Daily self‑care tips

• Inspect lesions weekly for signs of infection (redness, warmth, drainage).
• Keep the affected skin clean and moisturized; avoid harsh scrubbing.
• If a lesion becomes painful or ulcerated, seek prompt medical attention.
• Adhere strictly to prescribed lipid‑lowering therapy; set reminder alarms if needed.
• Maintain regular follow‑up appointments (every 3–6 months) to track lipid levels and cardiovascular risk.

Psychosocial considerations

Visible xanthomas can affect self‑esteem. Counseling, support groups for FH, or referral to a mental‑health professional can be helpful. Many national FH foundations (e.g., FH Foundation, FH Canada) provide peer‑support resources.

Monitoring for cardiovascular disease

• Annual lipid panel and LDL‑C goal assessment (often < 70 mg/dL for high‑risk patients, < 55 mg/dL for very high risk).
• Periodic non‑invasive imaging (carotid intima‑media thickness, coronary calcium scan) as instructed by a cardiologist.
• Prompt reporting of chest pain, dyspnea, or sudden weakness.

Prevention

Because tuberous xanthomas are a manifestation of uncontrolled hyperlipidemia, primary prevention focuses on early detection and treatment of lipid disorders.

• Family screening: First‑degree relatives of a patient with FH should have a fasting lipid panel and, if indicated, genetic testing before age 10.
• Screening guidelines: The American Heart Association recommends universal lipid screening once between ages 9‑11 and again between 17‑21, with earlier testing for high‑risk families.<sup>[6]</sup>
• Healthy lifestyle from childhood: Encourage balanced diet, regular activity, and avoidance of tobacco.
• Medication adherence: Educate patients about the importance of lifelong therapy, especially in genetic hypercholesterolemia.

Complications

Without effective lipid control, tuberous xanthomas are a marker for systemic atherosclerosis, leading to:

• Premature coronary artery disease – heart attacks can occur in the 30s–40s for homozygous FH.
• Stroke – due to carotid and cerebral artery atherosclerosis.
• Peripheral arterial disease – claudication, ulceration, limb ischemia.
• Pancreatitis – if severe hypertriglyceridemia coexists.
• Secondary infection of xanthomas – ulcerated lesions can become cellulitic.

When to Seek Emergency Care

---

References:

1. Nordestgaard BG, et al. “Familial hypercholesterolaemia is underdiagnosed and undertreated in general practice.” European Heart Journal. 2020;41:103–112.
2. Raal FJ, et al. “Homozygous familial hypercholesterolaemia: new insights and emerging therapies.” Nature Reviews Cardiology. 2022;19:345‑360.
3. Defesche JC, et al. “The Dutch Lipid Clinic Network criteria for familial hypercholesterolaemia.” Clin Biochem. 2021;94:1‑8.
4. Stone NJ, et al. “2018 ACC/AHA guideline on the management of blood cholesterol.” Circulation. 2019;139:e1082‑e1143.
5. Sabatine MS, et al. “Evolocumab and clinical outcomes in patients with heterozygous familial hypercholesterolemia.” New England Journal of Medicine. 2020;382:1507‑1519.
6. American Heart Association. “Guideline for the Primary Prevention of Cardiovascular Disease.” 2023. heart.org.

```